Personalis Inc
Change company Symbol lookup
Select an option...
PSNL Personalis Inc
PS Pluralsight Inc
POR Portland General Electric Co
PHI PLDT Inc
PD PagerDuty Inc
PBYI Puma Biotechnology Inc
PBF PBF Energy Inc
OGNG Bravo Enterprises Ltd
NNMIF Nearctic Nickel Mines Inc
NKTX Nkarta Inc
Go

Company profile

Personalis, Inc. is a cancer genomics company. The Company is focused on the development of therapies by providing molecular data about each patient’s cancer and immune response. The Company has designed NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. It also report on the entire transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.

Price
Delayed
$22.23
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 100 shares is on pace to be much lighter than PSNL's 10-day average volume of 689,288 shares.

100

Olive Garden parent Darden Restaurants same-restaurant sales slide 47.9% in Q4 through May 17

8:19 am ET May 19, 2020 (MarketWatch)
Print

Darden Restaurants Inc. (DRI) said same-restaurant sales fell 47.9% in the fourth quarter to date through May 17. The operator of the Olive Garden, LongHorn Steakhouse and Fine Dining chains, said it started to reopen dining rooms on April 27, limited to 25% and 50% capacity, based on local or state regulations. The company had about 49% of its dining rooms opened as of May 17 and expects to have more than 65% open with restrictions on capacity by the end of the month. Same-restaurant sales at Olive Garden were down 39.4% in the quarter to date through May 17, the company said. The company said its cash burn rate has improved to less than $10 million a week. The company has fully repaid a $750 million credit facility and had about $700 million in cash on hand as of May 17. It also has access to a $750 million credit facility. Shares were down 1.1% premarket and have fallen 31% in the year to date, while the S&P 500 has fallen 9%.

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

May 19, 2020 08:19 ET (12:19 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.